[Reduction of the duration of salmonella excretion in infants with Hylak forte].
Salmonella-enteritis is known to be an infectious disease of world-wide epidemiologic importance. The treatment of chronic carriers of pathogenic salmonella has shown to be a major therapeutic problem. In a controlled clinical study the efficiency of Hylak forte (containing products of metabolism of symbiotic bacteria) in the management of salmonellosis in infants was investigated. In patients receiving Hylak forte the period of faecal excretion of salmonella was significantly (p = 0.0022) shortened in comparison with the control-group. No side-effects did occur. Hylak forte proved to be effective in the therapy of enteritis in infants; the period of excretion of salmonella was significantly reduced.
Rudkowski
Z
Z
Klinik für infektiöse Kinderkrankheiten, Medizinischen Akademie Wroclaw, Polen.
Bromirska
J
J
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000890:Anti-Infective Agents; D015169:Colony Count, Microbial; D003968:Diarrhea, Infantile / Q000188:drug therapy* / Q000382:microbiology; D005243:Feces / Q000382:microbiology*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009930:Organic Chemicals; D012480:Salmonella Infections / Q000188:drug therapy* / Q000382:microbiology; D012477:Salmonella enteritidis / Q000187:drug effects* / Q000302:isolation & purification; D012486:Salmonella typhimurium / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; C071735:Hylak; D009930:Organic Chemicals
Verkürzung der Salmonellenausscheidungsdauer bei Säuglingen mit Hylak forte.